Shares of Galera Therapeutics Inc. (GRTX) skyrocketed 95% on Tuesday, thanks to corrected results from its ROMAN trial.
The ROMAN trial is a phase III study comparing the company's lead drug candidate Avasopasem against placebo for the treatment of severe oral mucositis in patients with locally advanced head and neck cancer undergoing standard-of-care radiotherapy.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com